Sector: MedicalZymoGenetics, Inc. (NASDAQ: ZGEN)
Headlines
- Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com
Nov 12, 2009 06:51 AM | BMY, HGSI, KG, ONXX, ZGEN
- CEL-SCI's H1N1 Clinical Study News Seen as Credibility Booster
Nov 06, 2009 02:39 PM | CVM, OMPI, ZGEN
- King Beats, But Earnings Down
Nov 05, 2009 04:13 PM | ALO, CEPH, KG, OMRI, PTIE, ZGEN
- ZymoGenetics Reports Third Quarter 2009 Financial Results
Nov 05, 2009 04:01 PM | ZGEN
- Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
Oct 31, 2009 05:30 PM | BMY, ZGEN
- ZymoGenetics to Webcast Presentation at Oppenheimer Healthcare Conference
Oct 28, 2009 06:00 AM | ZGEN
- ZymoGenetics Initiates Phase 2 Clinical Trial of PEG-Interferon lambda in Hepatitis C with Bristol-Myers Squibb
Oct 27, 2009 06:00 AM | BMY, ZGEN
- ZymoGenetics to Host Conference Call and Webcast on November 5, 2009 to Discuss Third Quarter 2009 Financial Results
Oct 15, 2009 06:00 AM | ZGEN
- Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Oct 05, 2009 08:04 AM | AMGN, ARRY, ONTY, SGEN, ZGEN
- Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009
Oct 01, 2009 10:45 AM | BMY, ZGEN
- Novo Nordisk: Half-Yearly Report
Aug 06, 2009 03:52 AM | NVO, PFE, ZGEN
- ZymoGenetics Reports Second Quarter 2009 Financial Results
Aug 03, 2009 04:51 PM | BMY, ZGEN
- StockPreacher.com Issues Trading Outlook for Hard to Treat Diseases Inc.
Aug 03, 2009 06:51 AM | HGSI, IMMU, JNJ, ZGEN
- ZymoGenetics to Host Conference Call and Webcast on August 3, 2009 to Discuss Second Quarter 2009 Financial Results
Jul 15, 2009 06:01 AM | ZGEN
- ZymoGenetics Appoints Eleanor L. Ramos, M.D. Senior Vice President and Chief Medical Officer
Jun 10, 2009 04:11 PM | ZGEN
- ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar®
May 31, 2009 02:01 PM | ZGEN
- Final Phase 2 Results for IL-21 in Renal Cell Cancer Show Tolerability and Enhanced Efficacy of Nexavar Combination
May 14, 2009 06:03 PM | ZGEN
- ZymoGenetics Reports Encouraging Preliminary Results from Phase 2 Study of IL-21 in Metastatic Melanoma Conducted by NCIC
May 13, 2009 08:40 AM | ZGEN
- ZymoGenetics to Webcast Presentation at Bank of America and Merrill Lynch 2009 Health Care Conference
May 07, 2009 06:01 AM | ZGEN
- ZymoGenetics Reports First Quarter 2009 Financial Results
May 05, 2009 04:01 PM | ZGEN
- Form 4 Miller Dennis M. For: Sep 16 (10K)
Sep 18, 2009 06:26 PM
- Form 3 Miller Dennis M. For: Sep 16 (10K)
Sep 18, 2009 06:25 PM
- Form 4 CARTER BRUCE L A For: Sep 16 (10K)
Sep 18, 2009 06:24 PM
- Form 4 JOHNSON JAMES A For: Aug 31 (10K)
Sep 02, 2009 01:48 PM
- Form 4 Zaruby Stephen W For: Jun 10 (10K)
Jun 12, 2009 03:33 PM
- Form 4 SORENSEN LARS REBIEN For: Jun 10 (10K)
Jun 11, 2009 06:39 PM
- Form 4 PENHOET EDWARD For: Jun 10 (10K)
Jun 11, 2009 06:32 PM
- Form 4 NIELSEN KURT ANKER For: Jun 10 (10K)
Jun 11, 2009 06:23 PM
- Form 4 MacCallum David For: Jun 10 (10K)
Jun 11, 2009 06:21 PM
- Form 4 ZYMOGENETICS INC For: Jun 10 Filed by: LEFF JONATHAN S (10K)
Jun 11, 2009 06:17 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ZGEN
|
Compare to S&P
|
| YTD |
89.67 %
|
56.67 %
|
| 4 Weeks |
-2.57 %
|
-3.09 %
|
| 12 Weeks |
0.00 %
|
-6.16 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 56.41 %
|
|
EPS Growth in Last Year: 59.52 %
|
|
Sales Growth in Last Quarter: 21.64 %
|
|
Sales Growth in Last Quarter: 131.19 %
|
|
